Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET
Company Participants
Marcio Souza – President and Chief executive Officer
Bernard Ravina – Chief Medical Officer
Alex Kane – Vice President Investor Relations and Corporate Communications
Conference Call Participants
Lauren Riaz – Piper Sandler
Laura Chico – Wedbush Securities
Yasmeen Rahimi – Piper Sandler
Ritu Baral – Cowen & Company
Myles Minter – William Blair
Douglas Tsao – H.C. Wainwright
Operator
Good day and thank you for standing by. Welcome to the Praxis Precision Medicines First Quarter 2022 Corporate Update, Question And Answer Conference Call. At this time, all participants are in a listen-only mode. After a short remark, there will be a question-and-answer session. [Operator Instructions] And now, my pleasure to hand the conference over to your first speaker today, Alex Kane, Vice President Investor Relations and Corporate Communications at Praxis. Thank you. Please go ahead.
Alex Kane
Thank you, Paul. Good afternoon, everyone and thank you for joining us today for our first quarter 2022 corporate update Q&A call. With me on the call is our President and Chief Executive Officer, Marcio Souza, our Chief Medical Officer, Bernard Ravina, and our CFO, Tim Kelly. Following the press releases and video update issued this afternoon, and we will focus today's call on your questions. We ask that you keep to one question initially, and then please feel free to rejoin the queue for follow-up questions as needed. Before we proceed, I would like to remind you that during today's call, we may make certain statements that are beliefs forward-looking and subject to various risks and uncertainties. For additional detail on forward-looking statements and the risks associated with our business, I encourage you to consult our SEC filings. With that, I will now pass the call over to the Operator to open up the line for Q&A. Operator.
Question-and-Answer Session
Operator
Thank, Souza. We will now begin the question and answer session. [Operator Instructions] Please stand by while we compile the Q&A roster. Your first question is from Yasmeen Rahimi with Piper Sandler. Please go ahead.
Lauren Riaz
Hey, guys. Thanks so much. This is Lauren Riaz. I have a couple of questions. The first one, what are some of the key lessons you guys learned from PRAX 944 data that could impact your views into the essential Phase 2b study? And then speaking a little bit, the enrollment, how that's going into that study and do you think that the essential population will capture similar demographic? Thank you.